Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer

Cancer Cell

Volumn 30, Issue 4, 2016, Pages 637-650

  Muvarak, Nidal E ^a,d   Chowdhury, Khadiza ^a,d   Xia, Limin ^b   Robert, Carine ^a,d   Choi, Eun Yong ^a,d   Cai, Yi ^b   Bellani, Marina ^c   Zou, Ying ^a   Singh, Zeba N ^a   Duong, Vu H ^a,d   Rutherford, Tyler ^e   Nagaria, Pratik ^a,d   Bentzen, Søren M ^a   Seidman, Michael M ^c   Baer, Maria R ^a,d,f   Lapidus, Rena G ^a,d   Baylin, Stephen B ^b,g   Rassool, Feyruz V ^a,d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e STEVENSON UNIVERSITY   (United States)

^f BALTIMORE VA MEDICAL CENTER   (United States)

^g VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

AML; breast cancer; DNA damage; DNA double strand break; DNA repair; DNMT inhibitor; DNMT1; PARP; PARP inhibitor; PARP trapping

Indexed keywords

AZACITIDINE; DECITABINE; DNA; DNA METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TALAZOPARIB; VELIPARIB; ANTINEOPLASTIC AGENT; CHROMATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PARP1 PROTEIN, HUMAN; PHTHALAZINE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER CELL LINE; CANCER SURVIVAL; CELL SELF-RENEWAL; CHROMATIN; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA METHYLATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LONG TERM SURVIVAL; MALE; MOUSE; MYELOID LEUKEMIA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; DOUBLE STRANDED DNA BREAK; DRUG EFFECTS; DRUG SCREENING; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; NONOBESE DIABETIC MOUSE; NUDE MOUSE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CHROMATIN; DNA BREAKS, DOUBLE-STRANDED; DNA METHYLATION; DRUG SYNERGISM; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED NOD; MICE, NUDE; PHTHALAZINES; POLY (ADP-RIBOSE) POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84991818044     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.09.002     Document Type: Article

References (65)

1. Agoston, A.T., Argani, P., Yegnasubramanian, S., De Marzo, A.M., Ansari-Lari, M.A., Hicks, J.L., Davidson, N.E., Nelson, W.G., Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J. Biol. Chem. 280 (2005), 18302–18310.
2. Audebert, M., Salles, B., Calsou, P., Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J. Biol. Chem. 279 (2004), 55117–55126.
3. Baylin, S.B., Jones, P.A., A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 11 (2011), 726–734.
4. Benafif, S., Hall, M., An update on PARP inhibitors for the treatment of cancer. OncoTargets Ther. 8 (2015), 519–528.
5. Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N.J., Helleday, T., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005), 913–917.
6. Caiafa, P., Guastafierro, T., Zampieri, M., Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns. FASEB J. 23 (2009), 672–678.
7. Carbone, M., Reale, A., Di Sauro, A., Sthandier, O., Garcia, M.I., Maione, R., Caiafa, P., Amati, P., PARP-1 interaction with VP1 capsid protein regulates polyomavirus early gene expression. J. Mol. Biol. 363 (2006), 773–785.
8. Ceccaldi, R., Liu, J.C., Amunugama, R., Hajdu, I., Primack, B., Petalcorin, M.I., O'Connor, K.W., Konstantinopoulos, P.A., Elledge, S.J., Boulton, S.J., et al. Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair. Nature 518 (2015), 258–262.
9. Chevanne, M., Zampieri, M., Caldini, R., Rizzo, A., Ciccarone, F., Catizone, A., D'Angelo, C., Guastafierro, T., Biroccio, A., Reale, A., et al. Inhibition of PARP activity by PJ-34 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line. J. Cell Physiol. 222 (2010), 401–410.
10. Chou, T.C., The Median Effect Principle and the Combination Index for Quantitation of Synergism and Antagonism. 1991, Academic Press.
11. Covey, J.M., D'Incalci, M., Tilchen, E.J., Zaharko, D.S., Kohn, K.W., Differences in DNA damage produced by incorporation of 5-aza-2′-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. Cancer Res. 46 (1986), 5511–5517.
12. D'Andrea, A.D., Susceptibility pathways in Fanconi's anemia and breast cancer. N. Engl. J. Med. 362 (2010), 1909–1919.
13. Damjanac, M., Page, G., Ragot, S., Laborie, G., Gil, R., Hugon, J., Paccalin, M., PKR, a cognitive decline biomarker, can regulate translation via two consecutive molecular targets p53 and Redd1 in lymphocytes of AD patients. J. Cell Mol. Med. 13 (2009), 1823–1832.
14. De Vos, M., Schreiber, V., Dantzer, F., The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem. Pharmacol. 84 (2012), 137–146.
15. Ding, N., Bonham, E.M., Hannon, B.E., Amick, T.R., Baylin, S.B., O'Hagan, H.M., Mismatch repair proteins recruit DNA methyltransferase 1 to sites of oxidative DNA damage. J. Mol. Cell Biol. 8 (2015), 244–254.
16. Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005), 917–921.
17. Fenaux, P., Inhibitors of DNA methylation: beyond myelodysplastic syndromes. Nat. Clin. Pract. Oncol. 2:Suppl 1 (2005), S36–S44.
18. Ghoshal, K., Bai, S., DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc) 43 (2007), 395–422.
19. Gibson, B.A., Kraus, W.L., New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat. Rev. Mol. Cell Biol. 13 (2012), 411–424.
20. Guastafierro, T., Cecchinelli, B., Zampieri, M., Reale, A., Riggio, G., Sthandier, O., Zupi, G., Calabrese, L., Caiafa, P., CCCTC-binding factor activates PARP-1 affecting DNA methylation machinery. J. Biol. Chem. 283 (2008), 21873–21880.
21. Guha, M., PARP inhibitors stumble in breast cancer. Nat. Biotechnol. 29 (2011), 373–374.
22. Ha, K., Lee, G.E., Palii, S.S., Brown, K.D., Takeda, Y., Liu, K., Bhalla, K.N., Robertson, K.D., Rapid and transient recruitment of DNMT1 to DNA double-strand breaks is mediated by its interaction with multiple components of the DNA damage response machinery. Hum. Mol. Genet. 20 (2011), 126–140.
23. Ha, K., Fiskus, W., Choi, D.S., Bhaskara, S., Cerchietti, L., Devaraj, S.G., Shah, B., Sharma, S., Chang, J.C., Melnick, A.M., et al. Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget 5 (2014), 5637–5650.
24. Haince, J.F., McDonald, D., Rodrigue, A., Dery, U., Masson, J.Y., Hendzel, M.J., Poirier, G.G., PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J. Biol. Chem. 283 (2008), 1197–1208.
25. Horton, J.K., Wilson, S.H., Predicting enhanced cell killing through PARP inhibition. Mol. Cancer Res. 11 (2013), 13–18.
26. Issa, J.P., DNA methylation as a therapeutic target in cancer. Clin. Cancer Res. 13 (2007), 1634–1637.
27. Issa, J.P., Kantarjian, H., Azacitidine. Nat. Rev. Drug Discov.(Suppl), 2005, S6–S7.
28. Issa, J.P., Kantarjian, H.M., Introduction: emerging role of epigenetic therapy: focus on decitabine. Semin. Hematol. 42 (2005), S1–S2.
29. Issa, J.P., Garcia-Manero, G., Giles, F.J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C.S., Cortes, J., Kantarjian, H.M., Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103 (2004), 1635–1640.
30. Issa, J.P., Roboz, G., Rizzieri, D., Jabbour, E., Stock, W., O'Connell, C., Yee, K., Tibes, R., Griffiths, E.A., Walsh, K., et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 16 (2015), 1099–1110.
31. Kantarjian, H., Issa, J.P., Rosenfeld, C.S., Bennett, J.M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 (2006), 1794–1803.
32. Kantarjian, H.M., Sekeres, M.A., Ribrag, V., Rousselot, P., Garcia-Manero, G., Jabbour, E.J., Owen, K., Stockman, P.K., Oliver, S.D., Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. Clin. Lymphoma Myeloma Leuk. 13 (2013), 559–567.
33. Kumar, C.C., Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer 2 (2011), 95–107.
34. Lan, Q., Zhang, L., Li, G., Vermeulen, R., Weinberg, R.S., Dosemeci, M., Rappaport, S.M., Shen, M., Alter, B.P., Wu, Y., et al. Hematotoxicity in workers exposed to low levels of benzene. Science 306 (2004), 1774–1776.
35. Lyko, F., Brown, R., DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J. Natl. Cancer Inst. 97 (2005), 1498–1506.
36. Mariano, G., Ricciardi, M.R., Trisciuoglio, D., Zampieri, M., Ciccarone, F., Guastafierro, T., Calabrese, R., Valentini, E., Tafuri, A., Del Bufalo, D., et al. PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression. Oncotarget 6 (2015), 15008–15021.
37. Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373 (2015), 1697–1708.
38. Moscariello, M., Iliakis, G., Effects of chromatin decondensation on alternative NHEJ. DNA Repair (Amst) 12 (2013), 972–981.
39. Murai, J., Huang, S.Y., Das, B.B., Renaud, A., Zhang, Y., Doroshow, J.H., Ji, J., Takeda, S., Pommier, Y., Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72 (2012), 5588–5599.
40. Murai, J., Zhang, Y., Morris, J., Ji, J., Takeda, S., Doroshow, J.H., Pommier, Y., Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J. Pharmacol. Exp. Ther. 349 (2014), 408–416.
41. Nussenzweig, A., Nussenzweig, M.C., A backup DNA repair pathway moves to the forefront. Cell 131 (2007), 223–225.
42. O'Farrell, A.M., Abrams, T.J., Yuen, H.A., Ngai, T.J., Louie, S.G., Yee, K.W., Wong, L.M., Hong, W., Lee, L.B., Town, A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 (2003), 3597–3605.
43. O'Hagan, H.M., Mohammad, H.P., Baylin, S.B., Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet., 4, 2008, e1000155.
44. O'Hagan, H.M., Wang, W., Sen, S., Destefano Shields, C., Lee, S.S., Zhang, Y.W., Clements, E.G., Cai, Y., Van Neste, L., Easwaran, H., et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell 20 (2011), 606–619.
45. Orta, M.L., Hoglund, A., Calderon-Montano, J.M., Dominguez, I., Burgos-Moron, E., Visnes, T., Pastor, N., Strom, C., Lopez-Lazaro, M., Helleday, T., The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions. Nucleic Acids Res. 42 (2014), 9108–9120.
46. Oz, S., Raddatz, G., Rius, M., Blagitko-Dorfs, N., Lubbert, M., Maercker, C., Lyko, F., Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells. Nucleic Acids Res., 42, 2014, e152.
47. Pachauri, V., Dubey, M., Yadav, A., Kushwaha, P., Flora, S.J., Monensin potentiates lead chelation efficacy of MiADMSA in rat brain post chronic lead exposure. Food Chem. Toxicol. 50 (2012), 4449–4460.
48. Patel, K., Dickson, J., Din, S., Macleod, K., Jodrell, D., Ramsahoye, B., Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res. 38 (2010), 4313–4324.
49. Patel, A.G., Sarkaria, J.N., Kaufmann, S.H., Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc. Natl. Acad. Sci. USA 108 (2011), 3406–3411.
50. Pedersen-Bjergaard, J., Christiansen, D.H., Desta, F., Andersen, M.K., Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 20 (2006), 1943–1949.
51. Prasad, R., Horton, J.K., Chastain, P.D. 2nd, Gassman, N.R., Freudenthal, B.D., Hou, E.W., Wilson, S.H., Suicidal cross-linking of PARP-1 to AP site intermediates in cells undergoing base excision repair. Nucleic Acids Res. 42 (2014), 6337–6351.
52. Rassool, F.V., Tomkinson, A.E., Targeting abnormal DNA double strand break repair in cancer. Cell Mol. Life Sci. 67 (2010), 3699–3710.
53. Reale, A., Matteis, G.D., Galleazzi, G., Zampieri, M., Caiafa, P., Modulation of DNMT1 activity by ADP-ribose polymers. Oncogene 24 (2005), 13–19.
54. Rogakou, E.P., Boon, C., Redon, C., Bonner, W.M., Megabase chromatin domains involved in DNA double-strand breaks in vivo. J. Cell Biol. 146 (1999), 905–916.
55. Rulten, S.L., Cortes-Ledesma, F., Guo, L., Iles, N.J., Caldecott, K.W., APLF (C2orf13) is a novel component of poly(ADP-ribose) signaling in mammalian cells. Mol. Cell Biol 28 (2008), 4620–4628.
56. Shen, Y., Rehman, F.L., Feng, Y., Boshuizen, J., Bajrami, I., Elliott, R., Wang, B., Lord, C.J., Post, L.E., Ashworth, A., BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin. Cancer Res. 19 (2013), 5003–5015.
57. Shen, Y., Aoyagi-Scharber, M., Wang, B., Trapping poly(ADP-ribose) polymerase. J. Pharmacol. Exp. Ther. 353 (2015), 446–457.
58. Sullivan, B.A., Optical mapping of protein-DNA complexes on chromatin fibers. Methods Mol. Biol. 659 (2010), 99–115.
59. Tobin, L.A., Robert, C., Nagaria, P., Chumsri, S., Twaddell, W., Ioffe, O.B., Greco, G.E., Brodie, A.H., Tomkinson, A.E., Rassool, F.V., Targeting abnormal DNA repair in therapy-resistant breast cancers. Mol. Cancer Res. 10 (2012), 96–107.
60. Tobin, L.A., Robert, C., Rapoport, A.P., Gojo, I., Baer, M.R., Tomkinson, A.E., Rassool, F.V., Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias. Oncogene 32 (2012), 1784–1793.
61. Tsai, H.C., Li, H., Van Neste, L., Cai, Y., Robert, C., Rassool, F.V., Shin, J.J., Harbom, K.M., Beaty, R., Pappou, E., et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21 (2012), 430–446.
62. Underhill, C., Toulmonde, M., Bonnefoi, H., A review of PARP inhibitors: from bench to bedside. Ann. Oncol. 22 (2011), 268–279.
63. Westman, M.K., Pedersen-Bjergaard, J., Andersen, M.T., Andersen, M.K., IDH1 and IDH2 mutations in therapy-related myelodysplastic syndrome and acute myeloid leukemia are associated with a normal karyotype and with der(1;7)(q10;p10). Leukemia 27 (2013), 957–959.
64. Wiegmans, A.P., Yap, P.Y., Ward, A., Lim, Y.C., Khanna, K.K., Differences in expression of key DNA damage repair genes after epigenetic-induced BRCAness dictate synthetic lethality with PARP1 inhibition. Mol. Cancer Ther. 14 (2015), 2321–2331.
65. Zampieri, M., Guastafierro, T., Calabrese, R., Ciccarone, F., Bacalini, M.G., Reale, A., Perilli, M., Passananti, C., Caiafa, P., ADP-ribose polymers localized on Ctcf-Parp1-Dnmt1 complex prevent methylation of Ctcf target sites. Biochem. J. 441 (2012), 645–652.